Small business impacts, the safety of cosmetic products aimed at women of color, and per- and polyfluoroalkyl substances (PFAS) were key concerns voiced by House Energy and Commerce Health Subcommittee members during an 11 March markup of the Cosmetic Safety Enhancement Act.
Cosmetic Safety Enhancement Act Advances In US House, Still Without Preemption
Approved by the House Energy and Commerce Health Subcommittee on 11 March, H.R. 5279 still lacks any concrete provisions regarding federal preemption of state and local requirements, though bill author and full committee chair Frank Pallone, D-NJ, remains committed to discussions on the subject. He recognized preemption as “a major issue that I know we have to deal with.”
More from United States
Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.
Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.
The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”
US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.